Annovis Announces Launch of Proposed Public Offering of Common Stock and Accompanying Warrants
Rhea-AI Summary
Annovis (NYSE: ANVS) launched a proposed underwritten public offering of common stock and accompanying warrants, which must be purchased together. All securities are offered by the company, with Canaccord Genuity as sole bookrunner.
Net proceeds are expected to fund Phase 3 development of buntanetap for Alzheimer’s disease, plus working capital and general corporate purposes. The offering’s completion, size and terms remain subject to market and other conditions.
AI-generated analysis. Not financial advice.
Positive
- Equity and warrant offering to fund Phase 3 buntanetap trial
- Proceeds also earmarked for working capital and corporate purposes
- Use of effective Form S-3 shelf may streamline capital raising
Negative
- Common stock and warrant issuance implies potential shareholder dilution
- Offering completion, size and terms remain uncertain and market dependent
News Market Reaction – ANVS
On the day this news was published, ANVS declined 0.77%, reflecting a mild negative market reaction. Argus tracked a trough of -21.7% from its starting point during tracking. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $523K from the company's valuation, bringing the market cap to $67.39M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Biotech peers showed mixed moves, with declines in names like BRNS and VRCA and gains in PSTV and RADX, suggesting ANVS’s financing is more stock-specific than sector-driven.
Previous Offering Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Apr 09 | Underwritten offering | Negative | -29.6% | Priced $10M underwritten stock and warrant offering at $1.90 per unit. |
| Oct 27 | Registered direct sale | Negative | +4.9% | Announced $3.4M registered direct offering at-the-market under NYSE rules. |
| Oct 15 | Offering closing | Negative | +12.2% | Closed $6.0M registered direct stock (or pre-funded warrant) offering. |
| Oct 10 | Registered direct deal | Negative | -22.7% | Entered agreements for $6M registered direct stock sale at $1.50 per share. |
| Feb 04 | Public equity raise | Negative | +0.0% | Closed $21M public offering of shares and warrants to fund Phase 3 buntanetap. |
Financing announcements have often led to negative or volatile moves, with several past offerings producing double-digit percentage swings.
Over the past year, Annovis has repeatedly used equity offerings and warrants to fund development of buntanetap. Prior financings in February 2025, October 2025, and April 2026 were conducted under the same Form S‑3 framework. Price reactions have been mixed, but the average move around these offering headlines was about -7.05%, underscoring that dilution-related news has frequently pressured the stock.
Historical Comparison
Past Annovis equity offerings (5 events) produced an average move of about -7.05%, showing financings have often been a pressure point for the stock.
Financings have repeatedly supported advancement of buntanetap into and through Phase 3 Alzheimer’s studies, using similar stock-and-warrant structures under the same S-3 framework.
Market Pulse Summary
This announcement outlines another underwritten stock-and-warrant financing to support Phase 3 development of buntanetap and general corporate needs. Historically, similar offerings around buntanetap have produced mixed price reactions, with an average move of about -7.05%. Investors tracking this story often watch use of proceeds, timing relative to trial milestones, and any changes in capital structure as additional details emerge.
Key Terms
underwritten public offering financial
warrants financial
phase 3 medical
shelf registration statement regulatory
form s-3 regulatory
prospectus supplement regulatory
bookrunner financial
common stock financial
AI-generated analysis. Not financial advice.
MALVERN, Pa., May 19, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced a proposed underwritten public offering in which it intends to offer and sell (i) shares of its common stock and (ii) accompanying warrants to purchase shares of common stock. The shares of common stock and the accompanying warrants will be issued separately but can only be purchased together in the proposed offering. All of the shares of common stock and the accompanying warrants will be offered by Annovis. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Canaccord Genuity is acting as the sole bookrunner in the offering.
Annovis intends to use the net proceeds from the offering for the continued clinical development of its lead compound buntanetap in a Phase 3 study for Alzheimer’s disease (AD), and for working capital and general corporate purposes.
The shares and the accompanying warrants are being offered by Annovis pursuant to an effective shelf registration statement on Form S-3 (No. 333-276814) previously filed with the Securities and Exchange Commission (SEC) on February 1, 2024 and declared effective by the SEC on February 12, 2024. A preliminary prospectus supplement and accompanying prospectus describing the terms of the proposed offering will be filed with the SEC. When available, copies of the preliminary prospectus supplement and the accompanying prospectus relating to this offering may be obtained from: Canaccord Genuity LLC, Attention: Syndication Department, One Post Office Square, 30th Floor, Boston, Massachusetts 02109, or by email at prospectus@cgf.com. Electronic copies of the preliminary prospectus supplement and accompanying prospectus will also be available on the SEC’s website at http://www.sec.gov.
This press release does not constitute an offer to sell or the solicitation of an offer to buy the securities, nor shall there be any sale of the securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or other jurisdiction.
About Annovis
Headquartered in Malvern, Pennsylvania, Annovis Bio, Inc. (NYSE: ANVS) is a Phase 3 clinical-stage biotechnology company developing treatments for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD). The Company's lead drug candidate, buntanetap (formerly posiphen), is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients. For more information, visit www.annovisbio.com and follow us on LinkedIn, YouTube, and X.
Forward-Looking Statements
This press release contains forward-looking statements under the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended, including, without limitation, statements regarding the consummation of the offering, the satisfaction of closing conditions and the intended use of proceeds from the offering. Actual results may differ due to various risks and uncertainties, including those outlined in the Company’s SEC filings under “Risk Factors” in its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update forward-looking statements except as required by law.
Contact Information:
Annovis Bio Inc.
101 Lindenwood Drive
Suite 225
Malvern, PA 19355
www.annovisbio.com
Investor Contact:
Alexander Morin, Ph.D.
Director, Strategic Communications
Annovis Bio
ir@annovisbio.com
